Evidence map›Paper›PMID 35755066›Full record

ArticleFrontiers in medicine2022

Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.

Yanfeng Bai, Huogen Wang, Xuesong Wu, Menghan Weng, Qingmei Han, Liming Xu, Han Zhang, Chengdong Chang, Chaohui Jin, Ming Chen and 2 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanfeng BaiDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huogen WangHithink RoyalFlush Information Network Co., Ltd., Hangzhou, China.
Xuesong WuDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Menghan WengDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qingmei HanDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Liming XuDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Han ZhangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chengdong ChangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chaohui JinHithink RoyalFlush Information Network Co., Ltd., Hangzhou, China.
Ming ChenHithink RoyalFlush Information Network Co., Ltd., Hangzhou, China.
Kunfeng LuoHithink RoyalFlush Information Network Co., Ltd., Hangzhou, China.
Xiaodong TengDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Molecular information about bladder cancer is significant for treatment and prognosis. The immunohistochemistry (IHC) method is widely used to analyze the specific biomarkers to determine molecular subtypes. However, procedures in IHC and plenty of reagents are time and labor-consuming and expensive. This study established a computer-aid diagnosis system for predicting molecular subtypes, p53 status, and programmed death-ligand 1 (PD-L1) status of bladder cancer with pathological images. Materials and Methods: We collected 119 muscle-invasive bladder cancer (MIBC) patients who underwent radical cystectomy from January 2016 to September 2018. All the pathological sections are scanned into digital whole slide images (WSIs), and the IHC results of adjacent sections were recorded as the label of the corresponding slide. The tumor areas are first segmented, then molecular subtypes, p53 status, and PD-L1 status of those tumor-positive areas would be identified by three independent convolutional neural networks (CNNs). We measured the performance of this system for predicting molecular subtypes, p53 status, and PD-L1 status of bladder cancer with accuracy, sensitivity, and specificity. Results: For the recognition of molecular subtypes, the accuracy is 0.94, the sensitivity is 1.00, and the specificity is 0.909. For PD-L1 status recognition, the accuracy is 0.897, the sensitivity is 0.875, and the specificity is 0.913. For p53 status recognition, the accuracy is 0.846, the sensitivity is 0.857, and the specificity is 0.750. Conclusion: Our computer-aided diagnosis system can provide a novel and simple assistant tool to obtain the molecular subtype, PD-L1 status, and p53 status. It can reduce the workload of pathologists and the medical cost.

Indexed as

bladder cancerdeep learningmolecular informationmolecular subtypesp53pathologyPD-L1

Identifiers

PMID35755066
PMCPMC9215327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.